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Abstract
Background: The TNF ligand family member TWEAK exists as membrane and soluble forms and is involved in the
regulation of various human inflammatory pathologies, through binding to its main receptor, Fn14. We have shown
that the soluble form of TWEAK has a pro-neuroinflammatory effect in an animal model of multiple sclerosis and
we further demonstrated that blocking TWEAK activity during the recruitment phase of immune cells across the
blood brain barrier (BBB) was protective in this model. It is now well established that endothelial cells in the
periphery and astrocytes in the central nervous system (CNS) are targets of TWEAK. Moreover, it has been shown by
others that, when injected into mice brains, TWEAK disrupts the architecture of the BBB and induces expression of
matrix metalloproteinase-9 (MMP-9) in the brain. Nevertheless, the mechanisms involved in such conditions are
complex and remain to be explored, especially because there is a lack of data concerning the TWEAK/Fn14
pathway in microvascular cerebral endothelial cells.
Methods: In this study, we used human cerebral microvascular endothelial cell (HCMEC) cultures as an in vitro
model of the BBB to study the effects of soluble TWEAK on the properties and the integrity of the BBB model.
Results: We showed that soluble TWEAK induces an inflammatory profile on HCMECs, especially by promoting
secretion of cytokines, by modulating production and activation of MMP-9, and by expression of cell adhesion
molecules. We also demonstrated that these effects of TWEAK are associated with increased permeability of the
HCMEC monolayer in the in vitro BBB model.
Conclusions: Taken together, the data suggest a role for soluble TWEAK in BBB inflammation and in the promotion
of BBB interactions with immune cells. These results support the contention that the TWEAK/Fn14 pathway could
contribute at least to the endothelial steps of neuroinflammation.
Keywords: CCL-2, hCMEC/D3, HMEC, IL-8, MMP-9, Neuroinflammation, TNFSF12, ZO-1
Background
TWEAK (tumor necrosis factor-like weak inducer of
apoptosis) is a member of the TNF ligand family and has
been described in both membrane and soluble forms [1].
It is now admitted that TWEAK is involved in the regu-
lation of many human pathologies, including lupus
nephritis, rheumatoid arthritis, and inflammatory bowel
diseases [2-5]. Moreover, increasing amounts of data
support the contention that TWEAK may play a dual
role in physiological versus pathological tissue responses
(for a review see [6]). By binding to its main receptor,
Fn14, TWEAK is known to induce proliferation of endo-
thelial cells in vitro and angiogenesis in vivo [7,8]. Using
transgenic mice that overexpress soluble TWEAK, we
have shown that the soluble form of TWEAK has a pro-
neuroinflammatory effect in an animal model of multiple
sclerosis (MS) [9]. Subsequently, using anti-TWEAK
monoclonal antibody injections in this model followed
by histopathological studies, we demonstrated that
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blocking TWEAK activity during the recruitment of im-
mune cells across the blood brain barrier (BBB) was pro-
tective [10]. The BBB constitutes a physical and metabolic
barrier that separates the CNS from the circulatory sys-
tem. It is composed of specialized brain microvascular
endothelial cells in close interaction with pericytes and
astrocytic end feet, and bound together by tight junctions.
Tight junctions between endothelial cells are formed by
transcellular proteins, including claudins and occludin,
that interact with the cytoskeleton via cytoplasmic pro-
teins, such as zonula occludens-1 (ZO-1).
Increased permeability of the BBB is an early and critical
event in the development and evolution of brain inflamma-
tory diseases. It is now well established that endothelial
cells and astrocytes, two of the major cellular components
of the BBB, are targets of TWEAK [7,11]. Moreover, it has
been shown that, when injected into mice brains, TWEAK
disrupts the architecture of the BBB and induces expres-
sion of matrix metalloproteinase-9 (MMP-9) in the brain
[12]. MMPs constitute a family of zinc-dependent secreted
or cell surface-associated endopeptidases that cleave matrix
components and a variety of pericellular proteins, includ-
ing cytokines, cell surface receptors, and adhesion mole-
cules. MMP-2 and MMP-9 (also known as gelatinases) are
probably among the most studied of the MMPs in the
CNS and intravenous administration of MMP-9 in vivo has
been shown to alter the properties of the BBB [13-16].
The importance of TWEAK in brain pathology is fur-
ther evidenced by data proving that TWEAK blocking
antibodies or Fn14 decoy receptors are efficient in ani-
mal models of ischemic stroke and brain edema [17-19].
Nevertheless, the mechanisms involved are complex
and, at times, results appear paradoxical; for instance,
treatment with TWEAK renders neurons tolerant to a
lethal hypoxic or ischemic injury [20]. A recent study on
post-mortem brain tissue from patients with MS indi-
cates that TWEAK is increased in meningeal macro-
phages, in astrocytes, and in microglia associated with
lesions and vascular abnormalities, and that Fn14 is
mainly localized in neurons and reactive astrocytes of
the cerebral cortex in highly infiltrated MS brains [21].
Interestingly, we have shown that in MS patients, mono-
cytes but not lymphocytes express membrane TWEAK
[22]. Taken together, the published data suggest a role
for membrane or soluble TWEAK in promoting mono-
cyte interaction with the BBB, BBB inflammation, or
monocyte diapedesis, and support the contention that
the TWEAK/Fn14 pathway could at least contribute to
the endothelial steps of neuroinflammation. However,
the molecular mechanisms involved in the effects of
TWEAK on the BBB remain to be determined. In this
study, we formed an in vitro model of the BBB using
human cerebral microvascular endothelial cell (HCMEC)
cultures to study the effects of soluble TWEAK on the
properties and integrity of the BBB. We showed that sol-
uble TWEAK induces an inflammatory profile on
HCMEC, especially by promoting secretion of cytokines,
by modulating production and activation of MMP-9,
and expression of cell adhesion molecules. We also
demonstrated that these effects of TWEAK are asso-
ciated with increased permeability of the HCMEC
monolayer in the in vitro BBB model.
Methods
Cells and culture reagents
The human brain endothelial cell line hCMEC/D3 is
described in [23]. hCMEC/D3 cells were seeded on
TranswellW filters (polycarbonate 12 well, pore size 3.0
μm, Corning, Lowell, MA) coated with type I collagen
(BD Biosciences, Paris, France), at a density of 350,000
cells/cm2 in commercially available complete medium
EGMW-2 (Lonza, Walkersville, MD), supplemented with
vascular endothelial growth factor, insulin-like growth
factor 1, epidermal growth factor, basic fibroblast growth
factor (FGF), hydrocortisone, ascorbate, penicillin-
streptomycin, and 2.5% FCS, (all from Lonza) in an incu-
bator at 37°C with 5% CO2. For differentiation and ex-
pression of junction-related proteins, the hCMEC/D3
cells were grown at confluence in a growth-factor-
depleted medium.
Primary HCMECs (Cell Systems, Kirkland, WA) were
grown on 0.2% gelatin-coated (Fisher Scientific, New York,
NY) tissue-culture plates in M199 medium supplemen-
ted with 20% fetal bovine serum (Gibco/BRL, Grand Is-
land, NY), 5% heat-inactivated human serum (Invitrogen,
Carlsbad, CA), 1% penicillin-streptomycin (Gibco/BRL),
and 12 ng/ml endothelial cell growth factor (Sigma
Aldrich, St. Louis, MO).
Human umbilical vein endothelial cells (HUVECs) and
a human acute monocytic leukemia cell line (THP-1)
were obtained from ATCC (Molsheim, France) and were
cultivated, respectively, in EBM-2 medium supplemented
with EBM-2 bullet kit (Lonza) and RPMI 1640 supple-
mented with 10% FCS and 1% penicillin-streptomycin
(Invitrogen).
For stimulation assays, cells were incubated for 3 h, 12 h,
or 24 h with recombinant human TWEAK (100 ng/ml,
Peprotech, Neuilly-Sur-Seine, France), Fc-TWEAK (1 μg/ml,
BiogenIdec, Cambridge, MA), its isotype control P1.17
(BiogenIdec), or recombinant human TNF (10 ng/ml,
Peprotech). In some experiments, cells were incubated with
recombinant human MMP-9 (rhMMP-9) from Calbiochem.
All reagents were endotoxin-free.
Flow cytometry
After trypsination, differentiated unstimulated or TWEAK-
stimulated hCMEC/D3 cells were pre-incubated on ice for
20 min with a solution containing PBS, 1% FCS, 0.02%
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sodium azide, and 25% purified human serum Immuno-
globulin G(Sigma Aldrich) to inhibit binding to Fc recep-
tors. After washes with a solution containing PBS, 1% FCS,
and 0.02% sodium azide, cells were incubated on ice for 20
min with fluorescein-conjugated anti-human ICAM-1
antibody, fluorescein-conjugated anti-human E-selectin
antibody (both fromR&DSystems,Minneapolis, USA), or
anti-human Fn14 phycoerythrin-conjugated antibody
(eBioscience, Paris, France). After three more washes,
cells were centrifuged and resuspended in PBS with 2%
paraformaldehyde. Fluorescence-activated cell sorting
(FACS) analysis was performed on a FACSCanto II (Bec-
ton Dickinson, Le Pont-De-Claix, France) using BD
FACSDiva software.
RNA extraction and RT-PCR analysis
Total RNA was prepared from cultures of hCMEC/D3,
HUVECs, and THP-1 using the RNeasy Lipid Tissue Mini
kit (Qiagen, Courtaboeuf, France). Single-strand cDNA
was synthesized from 1 μg of total RNA using oligo(dT)
12–18 primers (Invitrogen) and Moloney murine leukemia
virus reverse transcriptase (Invitrogen) under the condi-
tions indicated by the manufacturer. The sequences of the
specific forward (F) and reverse (R) primers were as fol-
lows: TWEAK-F (50-ATATATAGATCTATGGCCGCCCG
TCGGAGC-30), TWEAK-R (50-AGCCTTCCCCTCATCA
AAGT-30), Fn14-F (50-CCAAGCTCCTCCAACCACAA-
30), Fn14-R (50-TGGGGCCTAGTGTCAAGTCT-30), GAP
DH-F (50-GTCAGTGGTGGACCTGACCT-30), and GAP
DH-R (50-TGCTGTAGCCAAATTCGTT-30). Each cDNA
was amplified by Taq recombinant DNA polymerase (Invi-
trogen). The cDNAs were first denatured 3 min at 94°C,
then 40 PCR cycles were carried out with the following
profile: 45 s denaturation at 94°C, 30 s annealing at 59°C
for Fn14 or 52°C for GAPDH, and 1 min elongation at 72°
C. Cycles were followed by a 10 min final elongation at
72°C (Verity 96-well thermal cycler, Applied Biosystems
Foster City, CA). Controls were performed with template-
free PCR reactions. PCR products were analyzed by elec-
trophoresis on a 2% agarose gel containing ethidium
bromide. The expected sizes of the TWEAK, Fn14, and
GAPDH PCR products were 522 base pairs (bp), 242 bp,
and 226 bp, respectively.
TaqMan quantitative PCR
Real-time PCR (qPCR) experiments were carried out with
the 7500 Fast Real-Time PCR System (Applied Biosys-
tems). All reactions were performed using TaqMan Fast
Universal PCR Master Mix and two probes from the Taq-
ManW Gene Expression Assays (MMP-9, Hs00234579_m1
and Abelson (ABL): ABL-F (50-TGGAGATAACACTC
TAAGCATAACTAAAGGT-30), ABL- TaqMan reverse
probe (50-Fam6CCATTTTTGGTTTGGGCTTCACACCA
TT-Tamra-30), ABL-R (50-GATGTAGTTGCTTGGGACC
CA-30, used as reference) according to the manufacturer’s
instructions (Applied Biosystems). Each experiment used
25 ng of previously prepared hCMEC/D3 cDNA. Samples
were run in duplicates on the same 96-well plates and ana-
lyzed with the 7500 Software v2.0 (Applied Biosystems).
The thermal cycling conditions started with initial denatur-
ation at 95°C for 20 s, followed by 40 cycles of denaturation
at 95°C for 3 s and annealing and extension at 60°C for 30
s. Relative expression levels are determined according to
the ΔΔCt method where the expression level of the mRNA
of interest is given by 2-ΔΔCT where ΔΔCT = ΔCT target
mRNA − ΔCT reference mRNA (Abelson) in the same
sample.
Bromodeoxyuridine assay
hCMEC/D3 cell proliferation was determined by meas-
urement of bromodeoxyuridine (BrdU) incorporation
during DNA synthesis by chemiluminescence detection
using the Cell Proliferation ELISA BrdU kit (Roche
Applied Science, Meylan, France) according to the man-
ufacturer’s instructions.
Cytokine production
hCMEC/D3 differentiated cells were stimulated with
TWEAK or TNF for 24 h. Supernatants were collected,
centrifuged, and stored at −80°C until analysis. CCL-2,
IL-8, Il-6, and IL-10 levels were evaluated using com-
mercially available ELISA kits (Peprotech, and BD Bios-
ciences, San Jose, CA) according to the manufacturers’
instructions. All samples were analyzed in triplicate. The
detection threshold was 16 pg/ml of cytokine.
Transport assay
For transport experiments, we tested the passage of two
distinct molecules, Lucifer yellow (LY) (Sigma) and
BSA-FITC (Accurate Chemical and Scientific, Westbury,
NY). hCMEC/D3 cells or HCMECs were seeded and dif-
ferentiated on coated TranswellW filters. Both the upper
and lower chambers were washed with pre-warmed
Ringer-HEPES (RH) at 37°C. At time t = 0, LY or BSA-
FITC was applied in the apical compartment. After 60
min, detection of the fluorescent molecules was carried
out with a Beckman DTX800 luminometer with excitation
at 430/485 nm, and emission at 535 nm. Permeability
coefficients (Pe) take into account the relation between
the permeability of the monolayer and the permeability of
empty filters (pre-coated, without cells). Each condition
was tested in triplicate in each experiment.
Transepithelial electric resistance measurements
The assay setup of HCMECs for transepithelial electric re-
sistance (TEER) was the same as for the BBB permeability
assay. The HCMEC TEER was measured using the Elec-
trical Resistance System (Millicell-ERS-2; Millipore,
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Bedford, MA), following the manufacturer’s instructions.
In brief, coated inserts without cells were used as a blank
(minimum resistance). The electrical resistance of each in-
sert following treatment with TWEAK, P1.17, or TNF was
calculated by subtracting the blank from each reading.
Each condition was run in duplicate, and the resistance
measured twice for each well.
Western blot analysis
The following antibodies were used: goat anti-TWEAK
(R&D system, Abingdon, UK), rabbit anti-ZO-1 (1/200,
Invitrogen), and mouse anti-β-actin (1/3000, Sigma
Aldrich). Protein concentrations were determined using
the Lowry method (Bio-Rad, Hercules, CA). After boiling,
aliquots containing equal amounts of protein were loaded
in Laemmli buffer and separated by 8.5% sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS PAGE,
Bio-Rad) using a MiniBlot system (Bio-Rad). Proteins were
transferred onto nitrocellulose membranes (Amersham
Biosciences, Buckinghamshire, UK) in transfer buffer (25
mM Tris, 192 mM glycine, and 20% ethanol). Membranes
were incubated overnight in blocking buffer at 4°C and
then probed with the primary antibody against ZO-1,
β-actin, or TWEAK diluted in blocking buffer (Roche
Diagnostics, Mannheim, Germany). After washing, mem-
branes were incubated with a peroxidase-conjugated sec-
ondary antibody (Jackson Immunoresearch, West Grove,
PA). Finally, proteins were detected using a chemilumines-
cence kit (Roche Diagnostics). Films were digitized using
GeneTools software (Syngen, San Carlos, CA), and optical
densities of the bands were assessed using Scion Image
software (Scion Corporation, MA).
In situ zymography
To assess gelatinolytic activity of MMPs, hCMEC/D3 cells
were grown on glass coverslips and the medium was
supplemented to a final concentration of 5 mM CaCl2
and 10 μg/ml of intramolecularly quenched FITC-labeled
DQTM-gelatin (EnzCheck Collagenase kit from Molecular
Probes), as previously described [24,25]. After 2 h at 37°C
in a humidified atmosphere containing 5% CO2, cells were
rinsed in PBS, fixed with 4% paraformaldehyde (PFA) for 5
min, and incubated for 5 min with DNA intercalant
Hoechst #33258 (Molecular Probes, Eugene, OR). Cells
were observed with a Nikon E800 upright epifluorescence
microscope and digital images were acquired at 1,024 ×
1,024 pixels and saved in TIFF format. Fluorescence levels
were measured at the level of individual cells using image
J software; image editing was performed using Adobe
Photoshop (Adobe Systems, Paris, France).
Gel zymography
Standard methodology for gelatin zymography was used
to detect MMP-2 and MMP-9 expression levels via their
activity in cell supernatant or cell lysate samples, as
described previously [25]. Serum-free culture superna-
tants and lysates were collected and protein concentra-
tion was normalized as mentioned above. Equal
amounts of protein were subjected to 8% SDS PAGE
containing 1 mg/ml gelatin (Sigma Aldrich) in nondena-
turing, nonreducing conditions. After electrophoresis,
gels were washed twice for 30 min in 2.5% Triton X-100
to remove SDS and incubated for 48h in MMP-
activating buffer, 50 mM Tris–HCl, pH 7.5, with 10 mM
CaCl2 at 37°C. Gels were then stained with 0.1% Coo-
massie Brilliant Blue R-250 (Bio-Rad) for 3h and
destained with a solution containing 5% acetic acid until
clear bands of gelatinolysis appeared on a dark back-
ground. Gels were digitized using GeneTools software.
Immunohistochemistry
hCMEC/D3 cells grown on glass coverslips were fixed in
4% PFA and were incubated for 1 h at room temperature
with rabbit anti-ZO-1 (Invitrogen) or goat anti-MMP-9
(Abcam, Cambridge Science Park, UK) primary poly-
clonal antibodies. Subsequently, cells were incubated
with Alexa Fluor 488 or 594 anti-mouse or anti-goat
secondary antibodies (Invitrogen) followed by Hoechst
and mounted in fluorescent mounting medium (DAKO,
Glostrup, Denmark). The mounted slides were observed
with a Leica TCS SP2 confocal microscope (Leica Micro-
systems, Heidelberg, Germany). High magnification
images were acquired using a 633 HCX PL APO oil
immersion objective by sequential scanning to minimize
the crosstalk of fluorophores. For each channel, photo-
multiplier gains and offsets were adjusted to use full
image dynamic range. Images acquired at 1,024 × 1,024
pixels and saved in TIFF format were processed for colo-
calization analysis using ImageJ plug-in processing soft-
ware. Image editing was performed using Adobe
Photoshop.
MAPK inhibition studies
To investigate the involvement of mitogen-activated pro-
tein kinases (MAPKs) in MMP-9 expression following
TWEAK stimulation, we blocked c-RAF1 and MEK sig-
naling pathways using ERK2 and MEK1/2 specific inhi-
bitors (Sigma Aldrich) at working concentrations of 5
μM GW5074 and 0.5 μM U0126v. hCMEC/D3 cells
were cultured for 24h in the presence or absence of
TWEAK (100 ng/ml) and in the presence or absence of
the MAPK inhibitors; cell lysates and supernatants were
then collected and tested by gel zymography.
Results
hCMEC express Fn14 and are a target of TWEAK
In a first step, we used RT-PCR to study, in the
hCMEC/D3 cells, the expression of the mRNAs
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encoding TWEAK and its receptor Fn14. We found that
hCMEC/D3 cells express both TWEAK and Fn14 mRNAs
(Figure 1A). We next used flow cytometry to assess
TWEAK and Fn14 expression at the membrane in the
same cells. We show that hCMEC/D3 cells do not consti-
tutively express membrane TWEAK but constitutively ex-
press Fn14 on their surface (Figure 1C). TWEAK
exposure did not up-regulate TWEAK or Fn14 expression
at the cell surface (data not shown). Similarly, using
ELISA, we were not able to detect soluble TWEAK in the
culture supernatants of hCMEC/D3 (data not shown). In
agreement with data issued from Western blot analysis of
TWEAK expression by hCMEC/D3 cells (Figure 1B),
these results lead us to conclude that this cell line
expresses neither membrane nor soluble TWEAK.
TWEAK induces inflammation of HCMEC
Next, we studied the effects of TWEAK on hCMEC/D3
proliferation using a BrdU incorporation test. As indi-
cated in Figure 2, a 24h TWEAK exposure of the cells
induced proliferation. It is worth noting that the prolif-
erative effects of soluble TWEAK are significantly higher
than those of TNF.
To assess the potential inflammatory effects of
TWEAK on hCMEC/D3 cells and BBB inflammation,
we used ELISA to measure cytokine secretion in the cul-
ture supernatants after TWEAK or TNF exposure dur-
ing 24h, compared with nonstimulated cells (Figure 3).
We found that TWEAK significantly up-regulated proin-
flammatory cytokine (CCL-2, Il-8, and Il-6) production
in the hCMEC/D3 cells (Figure 3A). We obtained the
same results with primary HCMECs (Figure 3B). We
also showed that nonstimulated cells can produce low
levels of the anti-inflammatory cytokine Il-10 and that
this secretion is not significantly modulated by TWEAK
or TNF.
We also studied the effects of TWEAK stimulation on
the expression of hCMEC/D3 adhesion molecules. We
chose to explore E-selectin, which is involved in leukocyte
rolling, and ICAM-1, which is also up-regulated during in-
flammation, especially during firm leukocyte adhesion to
the endothelium. Using flow cytometry, we showed in
hCMEC/D3 that E-selectin membrane expression is not
significantly up-regulated by TWEAK, while ICAM-1
membrane levels are clearly increased following a 24h
TWEAK exposure (Figure 3C).
TWEAK increases leakiness of the in vitro model of the BBB
Lucifer yellow is a small hydrophobic molecule that pre-
sents low cerebral penetration and that is classically used
as a molecular marker of paracellular passage. To deter-
mine the effects of TWEAK on the permeability of a
monolayer of brain endothelial cells, hCMEC/D3 cells
were grown on Transwell filters and were exposed for
24h to TWEAK or TNF. We observed that TWEAK
induced a significant increase in Pe compared with the
nonstimulated condition Figure 4A. Similar results were
obtained with human primary HCMEC (Figure 4B). In
addition, we evaluated the TEER of the in vitro BBB
model upon TWEAK or TNF stimulation; we observed
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Figure 1 Expression of TWEAK and its receptor, Fn 14 by hCMEC/D3 cells. (A) Steady-state levels of TWEAK, Fn14, and GAPDH mRNAs were
assessed by semi-quantitative RT-PCR in cultures of hCMEC/D3, HUVECs, and THP-1 cells. PCR products were analyzed by electrophoresis on a 2%
agarose gel containing ethidium bromide and PCR products of the expected sizes were obtained for TWEAK (522 bp), Fn14 (242 bp), and GAPDH
(226 bp) indicating expression of all three genes at the mRNA level. (B) Western blot analysis of protein extracts from hCMEC/D3 or MDA-MB-231
cells (positive control) following separation by SDS PAGE and transfer onto nitrocellulose membranes. Membranes were probed with a primary
antibody against TWEAK. Note the absence of TWEAK protein expression by the hCMEC/D3 cells as compared with the MDA-MB-231 cells.
(C) FACS analysis of membrane bound Fn14 on differentiated hCMEC/D3 and HUVECs using anti-human Fn14 or isotype control phycoerythrin-
conjugated antibodies. Note the presence of Fn14 at the plasma membrane of the hCMEC/D3 cells.
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decreased TEER upon TWEAK stimulation (Figure 4C).
These data, associated with results from transport
experiments, lead us to conclude that soluble TWEAK
increases permeability of the human monolayers of brain
endothelial cells in the in vitro BBB model.
TWEAK stimulates MMP-9 expression and activity via
MAPK signaling pathway
Published reports indicate that TWEAK induces proteo-
lytic activity, notably metalloproteinase activity, in differ-
ent cell types [18,26]. We have also observed, in a
transcriptomic analysis of hMEC/D3 cells treated for 24
h by TWEAK, that the mRNAs encoding several MMPs
(MMP-12, MMP-17, MMP-28) were up-regulated, in-
cluding MMP-9 (data not shown). We thus evaluated
the effects of TWEAK on the gelatinolytic activity of
hCMEC/D3 cells. We used in situ zymography following
exposure to TWEAK (100 ng/ml) for 24 h. We found
significantly increased gelatinolytic activity in TWEAK-
or TNF-treated hMEC/D3 cells, compared with non-
treated cells. In some cells, gelatinolytic activity
appeared to delineate cells, suggesting localization at the
plasma membrane (Figure 5A). Among proteinases that
have gelatinolytic activity are the gelatinases MMP-2 and
MMP-9. hCMEC/D3 cells were exposed to TWEAK and
TNF for 24 h and gelatin-based gel zymography was per-
formed on cell lysates and serum-free media conditioned
by the treated and nontreated cells (Figure 5B). Non-
treated cells showed constitutive expression of a 68 kDa
gelatinase corresponding to the pro-form of MMP-2 and
weaker expression of the 105 kDa gelatinase correspond-
ing to the molecular weight of pro-MMP-9. Densitomet-
ric scanning of the zymograms indicated that MMP-2
levels (cellular and secreted forms) remained unchanged
following TWEAK and TNF treatment. Secreted levels
of MMP-9 also remained identical to control. In con-
trast, cellular MMP-9 pro-form levels, as well as active
MMP-9, increased significantly following TWEAK and
TNF treatment. To assess whether increased MMP-9
levels correlated with increased steady-state MMP-9
mRNA levels as suggested by the transcriptomics analysis,
we used qPCR; an increase in MMP-9 mRNA expression
was indeed observed in hCMEC/D3 cells 24 hours after
treatment with TWEAK and TNF (Figure 5C).
In fibroblast and skeletal muscle cells, TWEAK is
reported to activate MAPKs and regulate the expression
of MMP-9 [27,28]. To assess whether this is also the
case in brain endothelial cells, cultures were incubated
for 1 h before adding TWEAK in the presence GW5074
and U0126, which are respectively inhibitors for ERK1/2
and MEK2 involved in the MAPK signaling pathways.
Densitometric scanning of zymograms indicates that
MAPK inhibitors efficiently suppressed the up-regulation
of MMP-9, whose expression remained at basal levels
(Figure 5D) and had no effect on the expression or activity
levels of MMP-2 (data not shown). These results suggest
that in human brain endothelial cells, TWEAK induces
MMP-9 up-regulation via the MAPK signaling pathways.
We next evaluated the effects of exogenous recombinant
human MMP-9 on the permeability of the hCMEC/D3
monolayer. The addition of 250 ng/ml rhMMP-9 for 24h
enhanced the permeability of the endothelial cell mono-
layer by 20% (Figure 5E). Considering that TWEAK
increases both Pe of the hCMEC/D3 monolayer and
MMP-9 levels and that exogenously applied rhMMP-9
also increases Pe, we assessed whether TWEAK-increased
Pe could be modulated by MMP inhibitors. TWEAK and
the broadband MMP inhibitor RXPO3 were applied to the
hCMEC/D3 monolayer for 24h and Pe was assessed. We
find that inhibition of MMP activity neither prevents bar-
rier impairment nor leads to a significant barrier recovery
(Figure 6F).
To investigate the cellular distribution of MMP-9 in non-
treated and TWEAK-treated endothelial cells, we used an
antibody for MMP-9 whose specificity had been previously
validated on neuroblastoma N2a cells transfected with
MMP-9-GFP-constructs [25]. In nontreated and TWEAK-
treated hCMEC/D3 cells, MMP-9 showed a punctuate,
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Figure 2 Proliferative effects of TWEAK on hCMEC/D3.
Unstimulated (CTRL) or stimulated (TWEAK, TNF) hCMEC/D3 cell
proliferation was determined by measurement of BrdU incorporation
during DNA synthesis by chemiluminescence detection. Results
indicate increased hCMEC/D3 cell proliferation on TNF and TWEAK
stimulation, the latter being more prominent. * p < 0.05 according
to Student’s t test.
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vesicular-like pattern distributed throughout the cytoplasm
(Figure 6A). MMP-9 immunolabeling was clearly increased
in the TWEAK- and TNF-treated cells. Detailed analysis of
the labeled endothelial cells also indicates perinuclear accu-
mulation of MMP-9, presumably in the Golgi and trans-
Golgi network. We show that MMP-9 is localized in part
at the membrane of brain endothelial cells. In agreement
with our previous findings in other cell types of the CNS
[25,29], MMP-9 was also localized in the nucleus of brain
endothelial cells (Figure 6B).
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Figure 3 hCMEC/D3 cells produced chemokines and membrane ICAM-1 after TWEAK exposure. (A) ELISA analysis of CCL-2, IL-8, Il-6, and
IL-10 levels in the supernatants of hCMEC/D3 differentiated cells stimulated with TWEAK or TNF for 24 h or not (CTRL); all samples were analyzed
in triplicates. The detection threshold was 16 pg/ml of cytokine. Note the increased secretion of CCL-2, Il-8, and Il-6. (B) Primary HCMECs were
stimulated with Fc-TWEAK or its isotype control P1.17 for 24 h or not (CTRL). Supernatants were collected and Il-6, IL-8, and CCL-2; levels were
evaluated by ELISA. All samples were analyzed in triplicate. The detection threshold was 16 pg/ml of cytokine. (C) FACS analysis of membrane
expression of ICAM-1 and E-selectin in differentiated hCMEC/D3 and HUVEC cells stimulated with TWEAK or TNF for 24 h or not (CTRL). Cells were
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TWEAK down-regulated expression of ZO-1, a major
component of HCMEC tight junctions
Because ZO-1 is exclusively located in tight junctions
but also constitutes a substrate for MMP-9 [30], we
assessed expression of this protein in the hCMEC/D3
cells under TWEAK exposure. Using double labeling
experiments combining antibodies against MMP-9
and against ZO-1, we show that MMP-9 and ZO-1
can be colocalized at discrete areas of the plasma
membrane (Figure 6A, 6C). Using Western blot ana-
lysis, we show that soluble TWEAK induced a down-
regulation of the two isoforms, α+ and α−, of ZO-1
(Figure 6D).
Discussion
TWEAK has been shown to induce various biological
responses through binding to its receptor Fn14 [31], in-
cluding angiogenesis, osteoclastogenesis, skeletal muscle
wasting, and apoptosis [27,31]. TWEAK is also known
as a proinflammatory cytokine involved in tissue injuries
including brain inflammatory processes [10,17,22,32].
Disruption of the BBB occurs in a number of patho-
logical conditions, including cerebral ischemia, head
trauma, CNS infections, and MS [12,33-37], and results
in the development of cerebral edema, which is a
frequent cause of mortality in patients. Thus, under-
standing the pathophysiological processes leading to
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Figure 4 WEAK increased Lucifer yellow permeability in an in vitro model of the BBB. (A) hCMEC/D3 cells were differentiated on coated
TranswellW filters and stimulated (TWEAK, TNF) or not (CTRL) during 24 hours. At time t = 0, Lucifer yellow (LY) was applied in the apical
compartment. After 60 min, LY fluorescence was assessed in the lower compartment and the permeability coefficient (Pe) was calculated taking
into account the relation between the permeability of the monolayer and the permeability of empty filters (pre-coated, without cells). Each
condition was run in triplicate in three independent experiments. TWEAK induces increased passage of LY across the hCMEC/D3 cell monolayer.
(B) The passage of BSA-FITC was used to assess transport through primary HCMEC seeded and differentiated on coated filters. Primary HCMEC
were stimulated with Fc-TWEAK or TNF for 24 h or not (CTRL). At time t = 0, BSA-FITC was applied in the apical compartment. After 60 min, the
fluorescence levels were assessed in the basal compartment. Each condition was run in triplicate. (C) The assay setup of HCMEC for TEER was the
same as for the BBB permeability assay described in (B). HCMEC TEER was measured by the Electrical Resistance System Millicell-ERS-2. Coated
inserts without cells were used as a blank (minimum resistance). The electrical resistance of each insert following treatment with TWEAK, P1.17, or
TNF was calculated by subtracting the blank from each reading. Each condition was run in duplicate, and the resistance measured twice for each
well. In (A), (B) and (C) * p < 0.05 according to Student’s t test.
Stephan et al. Journal of Neuroinflammation 2013, 10:9 Page 8 of 14
http://www.jneuroinflammation.com/content/10/1/9
050
100
150
CTRL   TWEAK   TNF
B
A
CTRL                  TWEAK                         TNF
*
*
C
0
2
4
6
8
CTRL      TWEAK       TNF 0
50
100
150
D
CTRL      TWEAK    TWEAK    TWEAK
+ GW504  + UO1206
0
50
100
150
200
CTRL TWEAK TNF
CTRL    TWEAK   TNF CTRL    TWEAK   TNF CTRL    TWEAK   TNF
Pro-MMP-9
MMP-9
Pro-MMP-2
MMP-2
kDa
105
68
Lysates                 Culture medium 
Upper                Lower
Pro-MMP-9
*
*
*
*
*
MMP-9
MMP-9
a b  c d
0
50
100
150
Pe
 re
la
tiv
e
 to
 c
on
tro
l (%
)
CTRL  rhMMP-9
0
50
100
150
200
Pe
 re
la
tiv
e
 to
 c
on
tro
l (%
)
CTRL       TWEAK       TNF CTRL  TWEAK   TNF
without  RXPO3 with  RXPO3
E F
*
*
*
*
*
Figure 5 (See legend on next page.)
Stephan et al. Journal of Neuroinflammation 2013, 10:9 Page 9 of 14
http://www.jneuroinflammation.com/content/10/1/9
disruption of the barrier and increased permeability is
crucial for the development of new therapeutic strat-
egies. In vivo administration of TWEAK in mice has
been shown to induce cerebrovascular permeability [12].
In this study, we assessed the effects of TWEAK at the
molecular level on a human in vitro model of the BBB.
We show for the first time that soluble TWEAK: (i)
induced proliferation of human brain endothelial cells;
(ii) promoted an inflammatory pattern of these cells,
notably by stimulating secretion of cytokines, (iii) modu-
lated the levels of cell adhesion molecules which is cru-
cial for leukocyte-endothelium interaction and finally,
(iv) modulated the expression of MMP-9 and ZO-1 and
increased the permeability of the endothelial cell
monolayer.
We and others have previously shown that TWEAK/
Fn14 interaction induces proliferation of astrocytes and
endothelial cells, production of proinflammatory cyto-
kines and expression of adhesion molecules [7,8,11].
Nevertheless, there was a lack of data about the micro-
vascular endothelial cerebral cells involved in the BBB,
which represent a major cellular component of neuroin-
flammation. Data generated by the study of TWEAK on
HUVECs, for example, cannot be directly applicable to
interactions between white blood cells and endothelial
cells at the BBB. We demonstrated in this study that
immortalized or primary HCMECs respond to TWEAK/
Fn14 interaction by adopting an inflammatory profile
that is associated with an increased permeability of the
monolayer formed by these cells in an in vitro BBB
model. It is worth noting that the proliferative property
of TWEAK on hCMEC/D3 is much more dramatic than
that on cytokine induction. This observation could be
explained by either a specific action of TWEAK or a
synergistic effect of TWEAK combined with a TWEAK-
enhanced bFGF endothelial cell proliferative effect. In
fact, our proliferation culture medium is enriched in
bFGF and it has been shown by others that TWEAK can
act in concert with bFGF to regulate endothelial cell
proliferation [7,8]. Our results suggest that soluble or
membrane TWEAK expressed by blood monocytes or
nervous tissue macrophages may regulate leukocyte re-
cruitment across the BBB by promoting the production of
the CCL-2 and IL-8 chemokines by HCMEC, but also by
enhancing the expression of ICAM-1 at their cell surface,
an adhesion molecule involved in leukocyte-endothelium
interaction during transendothelial migration [38]. Inter-
estingly, CCL2, known to be involved in neuroinflamma-
tory processes, not only promotes leukocyte chemotaxis
but also compromises the BBB [39]. In fact, CCL2
mediates redistribution of tight-junction proteins and
reorganization of the actin cytoskeleton in brain endothe-
lial cells [40-42], leading to altered BBB functions. We
thus suggest that induced secretion of CCL2 by HCMECs
may be one of the processes elicited by TWEAK to in-
crease BBB permeability.
Our results suggest that TWEAK induced the expres-
sion of MMP-9 through the activation of MAPK signal-
ing pathway in human cerebral endothelial cells. The
ability of TWEAK to modulate MMP-9 expression was
previously reported in a few studies including the work
of Chicheportiche et al. in 2002 [43]. Li et al. [27] have
also shown that TWEAK affects the expression of sev-
eral genes of the MMP family in skeletal muscle. It was
also proposed that TWEAK plays a role in MMP-3 and
MMP-1 up-regulation [43,44]. Finally, TWEAK has been
shown to enhance MMP-9 expression in several cell
types, including macrophages [45], C2C12 myotubes
[28], and mouse astrocytes [12]. Nevertheless, the ex-
pression of these MMPs and their potential role in struc-
tural and functional deterioration of BBB during
pathological conditions remain largely unknown. Asahi
et al. [15,30] demonstrated that MMP-9 has a direct ef-
fect on the permeability of the neurovascular unit. Inter-
estingly, we show that cerebral endothelial cells under
TWEAK treatment express more of the pro-MMP-9
than of the active MMP-9. This is in agreement with
several studies involving gelatin zymography showing
(See figure on previous page.)
Figure 5 Gelatinase activity and expression in hCMEC/D3 cells treated with TWEAK and effects of MMP inhibition. (A) Epifluorescence
photomicrographs in live hCMEC/D3 cells with gelatin-quenched fluorescent substrate (green), and nuclear intercalant Hoechst (blue). Net
gelatinolytic activity (a) increased with TWEAK (b) and TNF (c), shown by densitometric analysis (d). Scale bar, 10 μm. (B) Gel zymography
showing expression and secretion of MMP-2 and MMP-9 in cell lysates and culture media after treatment of hCMEC/D3 with TWEAK or TNF.
Nonstimulated endothelial cells express pro-MMP-9, pro-MMP-2, and active MMP-2. Active MMP-9 is barely detected. Control cells secrete pro-
MMP-9 and pro-MMP-2 in both compartments, and low levels of their active forms. In cell lysates, TWEAK or TNF treatment has no significant
effect on the expression of pro- and active MMP-2 but significantly induces pro-MMP-9 and active MMP-9 expression; there is no effect on the
secreted forms of MMP-2 and MMP-9. (Densitometric analysis of pro-MMP-9 zymograms of the lysates.) (C) MMP-9 mRNA quantification by qPCR,
expressed as fold change ratios of treated versus control samples after normalization with Abelsson mRNA. (D) Inhibition of TWEAK-induced
MMP-9 activity by ERK and JUNK inhibitors in hCMEC/D3 cells. After serum-starvation for 24 h, cells were pretreated with ERK and JUNK inhibitors
(5 μM GW5074 and 0.5 μM U0126, respectively) for 1 h and then treated with TWEAK. TWEAK readily induces MMP-9 expression. Both inhibitors
significantly inhibit TWEAK-induction of MMP-9 in the cell lysate (densitometric analysis of zymograms). (E) Exogenous recombinant human MMP-
9 (rhMMP-9, 250 ng/ml for 24 h) enhanced the permeability (Pe) of the endothelial cell monolayer by 20%. (F) Inhibition of MMP activity with the
broad-spectrum MMP inhibitor RXPO3 for 24 h has no effect on TWEAK- or TNFα-increased Pe and barrier impairment. In (A,B,D-F) * P < 0.05
according to Student’s t test.
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that it is essentially pro-MMP-9 that is induced in glial
cells, neurons, and endothelial cells [16,29,46,47]. This
observation may reflect a rapid and local activation of
MMP-9 in these cells by sharp activation mechanisms.
Our study provides the first evidence showing that in
endothelial cells, it is only the cellular MMP-9,
presumably including membrane bound-MMP-9, that is
increased by TWEAK, while there is no induction of
secreted MMP-9. We hypothesize that MMP-9 may play
a local role in cytosolic and membrane proteolytic activ-
ity under physiological and pathological conditions. A
number of in vitro results, including some from our
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Figure 6 MMP-9 and Zo-1 expression and distribution in hCMEC/D3 cells treated with TWEAK. (A) Colabeling immunocytochemistry
showing expression and distribution of MMP-9 and ZO-1 in control (CTRL), TWEAK-, and TNFα-treated hCMEC/D3 cells. MMP-9 showed a
punctuate, vesicular-like pattern distributed throughout the cytoplasm that was increased in the TWEAK- and TNFα-treated cells. Superimposition
of MMP-9 and ZO-1 images shows colocalization of both proteins (Merge (×20), scale bar 10 μm) in yellow-orange along the plasma membrane,
visible as distinct puncta (arrows in Merge (×40), scale bar 2.5 μm). Note the global down-regulation of ZO-1 expression in TWEAK and TNF-
treated hCMEC/D3 cells as compared with CTRL. (B) Confocal analysis of a single z-axis plan of the TWEAK-treated cells shows nuclear
accumulation of MMP-9. Scale bar 2 μm. (C) Kymographs were constructed and analyzed with ImageJ software from single-pixel width lines
taken from each channel of the confocal images in A (Merge (×40)). Profiles of the signal intensities of MMP-9 (green line) and ZO-1 (red line)
measured along the single-pixel width lines drawn in Merge (×40) indicate colocalization. (D) Western blot analysis of protein extracts from
TWEAK-treated hCMEC/D3 cells following separation by SDS PAGE and transfer onto nitrocellulose membranes, which were probed with primary
antibodies against ZO-1 and actin. Both TWEAK and TNF treatments diminish ZO-1 expression in the hCMEC/D3 cells. Representative Western blot
of three independent experiments.
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laboratory, indicate that pro- and active forms of MMP-
9 are also localized in the membrane, for example in
neural cells [25,29]. Previous studies suggest that activa-
tion of MMP-9 pro-enzyme occurs by binding at the cell
surface, and that the activated enzyme is then rapidly
degraded, preventing excess activity [48]. Therefore, only
very low levels of active MMP-9 may be present in cells
at any given time. Further studies are required to iden-
tify potential MMP-9 activation events and elucidate
their time course in more detail. We also reported
MMP-9 localization in the nucleus of hCMEC/D3 and
show increased nuclear levels following stimulation with
TWEAK. While MMP-9-interacting proteins or targets
in the cell nucleus are unknown, there is rationale for its
interaction with Ku, a nuclear DNA repair protein, con-
sidering that both proteins have been shown to interact,
notably at the cell surface [49].
Treatment of hCMEC/D3 with MEK and ERK inhibi-
tors significantly reduced TWEAK-induced MMP-9
gelatinolytic activity, supporting the idea that MAPK
pathways are involved. It has been shown that the bind-
ing of TWEAK to its receptor Fn14 could result in acti-
vation of the MAPK pathway in vitro [50,51]. Moreover,
activation of MAPK pathways has been described in
endothelial cells in several neuropathological processes,
such as cerebral ischemia [52,53], head trauma [54], and
seizures [55].
Our data support the contention that MMP-9 rather
than MMP-2 contributes at least in part to the increased
permeability of the HCMEC monolayers. However, we
cannot exclude the possibility that other MMPs or pro-
teinases from other families also contribute to BBB de-
mise. Indeed, while we show that recombinant MMP-9
can increase the permeability of our BBB model, and
while MMP inhibitors have proven beneficial effects in,
for example, animal models of hypoxia ischemia [56], we
also show that increased BBB permeability in vitro can-
not be prevented with a broad-spectrum MMP inhibitor.
One hypothesis is that active MMP-9 (or other MMPs)
was not efficiently inhibited if present in the plasma
membrane. Indeed, it has been shown that even high-
affinity endogenous inhibitors for MMP-9, such as
TIMP-1, cannot inhibit MMP-9 when present at the
plasma membrane [57]. Proteinases may synergize with
other molecular events to promote BBB demise, for
example, CCR2-dependent CCL-2 biological effects
described during neuroinflammation [40,58]. Tight-
junction integrity is known to play a key role in brain
homeostasis and a loss of tight-junction proteins is com-
monly observed in neuroinflammatory and neurodegen-
erative disorders. Tight-junction proteins, including ZO-
1, are thought to have both structural and signaling roles
and are linked to the actin skeleton of the endothelial
cells. We show that treatment of HCMEC with soluble
TWEAK resulted in decreased levels of ZO-1. In a previ-
ous study, an emphasis has been placed on the fact that
ZO-1, albeit intracellular, is a substrate of MMP-9 [59]
while in vivo studies underlined that this substrate was
degraded by MMP-9 after ischemia [16]. Moreover, it was
recently shown that suppression of MMP-9 expression in
brain microvascular endothelial cells induced an increase
of gene and protein expression of ZO-1 in these cells [60].
In summary, our study demonstrates that TWEAK mod-
ulates the expression levels of cytokines, CAMs, tight-
junction proteins, and MMPs in cultured endothelial cells,
and alters the permeability of an in vitro BBB model based
on these cells. These results are in agreement with our pre-
vious results demonstrating in vivo a role for TWEAK in
regulation of immune cell infiltrates in the CNS during ex-
perimental autoimmune encephalomyelitis (EAE) [10].
We propose a model in which soluble TWEAK is
released during neuro-inflammation, or membrane TWEAK
is presented by monocytes, and binds to Fn14 receptors on
CNS endothelial cells, resulting in secretion of proinflamma-
tory and chemoattractant cytokines, expression of cell adhe-
sion molecules, activation of the MAPK pathway, and
induction of MMP-9, with a resulting disruption of the
tight-junction structure and increase in BBB permeability
and diapedesis. Our studies predict that it may be beneficial
to block the TWEAK/Fn14 pathway as a therapeutic modal-
ity in BBB breakdown.
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